Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

PASCAL Precision-GDMT Registry (PASCAL)

11. maj 2026 opdateret af: Ceric Sàrl

Improvement in Guideline-Directed Medical Therapy After Tricuspid Transcatheter Edge-to-Edge Repair in Participants With Reduced Left Ventricular Function

The goal of this observational study is to demonstrate that successful tricuspid valve repair with the PASCAL Precision System in participants with at least severe tricuspid insufficiency and left ventricular dysfunction will be associated with an improvement in up-titration of guideline-directed medical therapy (GDMT). The main question it aims to answer is:

Does the tricuspid insufficiency repair with the Pascal Precision System increases the dose of the medications used for heart failure therapy in the study population 12 months after tricuspid repair, as compared to the dose taken at baseline.

Participants undergoing tricuspid repair and fulfilling all inclusion/exclusion criteria will be asked to answer heart failure assessment as well as quality of life questionnaires at baseline and at 12 months post intervention. Medication monitoring will be performed throughout the study.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Undersøgelsestype

Observationel

Tilmelding (Anslået)

50

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Participants from France with at least severe tricuspid regurgitation with associated left ventricular dysfunction

Beskrivelse

Inclusion Criteria:

  • Participants of age ≥ 18 years
  • ≥ severe tricuspid regurgitation
  • LVEF < 50%
  • Written informed consent of the patient or her/his legal representative
  • Patient understands the purpose, the potential risks as well as benefits of the trial and is willing to participate in all parts of the follow-up
  • Planned follow-up within a dedicated heart failure clinic as part of routine care.

Exclusion Criteria:

  • Anatomy unsuitable for TEER as determined by local heart team
  • severe mitral regurgitation (defined as an EROA>40 mm2) treated (surgically or percutaneously) less than 3 months prior
  • severe left ventricular dysfunction (defined as an LVEF <20%)
  • systolic pulmonary artery pressure >70 mmHg (right heart catheterization)
  • prior tricuspid valve intervention
  • severe leaflet degeneration or tricuspid valve anatomy precluding successful device placement
  • primary tricuspid valve disease
  • COPD requiring home oxygen therapy
  • active endocarditis, or recent episode within 4 weeks of discontinuation of antibiotic therapy
  • participants with unstable hemodynamic condition
  • significant co-morbidities resulting in an expected less than 12-month life expectancy
  • The presence of other anatomic or comorbid conditions or other medical, social or psychological conditions that in the investigators' opinion could limit the subject's ability to participate in the clinical study and its follow-up.
  • Participants under judicial protection, guardianship or curatorship or if they are deprived of their liberty by judicial or administrative decision
  • Participation in another trial, which would lead to deviations in the preparation or performance of the intervention or the post-implantation management from this protocol

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Kohorter og interventioner

Gruppe / kohorte
Participants with at least severe tricuspid regurgitation and associated left ventricular dysfuntion
Participants of the cohort undergoing a successful T-TEER will be enrolled in the study.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in GDMT score at 12 months, compared to baseline
Tidsramme: From enrollment up to 12 months post-procedure

The GDMT score is calculated by adding all scores of each HF therapy. The minimum score corresponds to no medication taken and is 0. The maximum score is 11 and corresponds to all medications taken at the maximum dose. An intermediate score would be all medications taken at the intermediate dose and would be 6 (ACEi/ARB/ARNI = 2, BB = 2, MRA at 50-99% = 2). A low score would be ACEi/ARB/ARNI, BB and MRA at low dose and would be 3.

The dose of diuretics, although not included in the GDMT score, should be collected and considered separately.
From enrollment up to 12 months post-procedure

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Heart failure hospitalisation rate at 12 months
Tidsramme: From enrollment up to 12 months
Number of hospitalizations related to heart failure at 12 months divided by the number of patients
From enrollment up to 12 months
All-cause hospitalisation rate at 12 months
Tidsramme: From enrollment up to 12 months
Number of hospitalisations for all cause at 12 months divided by the number of patients
From enrollment up to 12 months
NT-pro BNP at 12 months compared to baseline
Tidsramme: At enrollment and at 12 months
Comparison of the 12-months level of NT-pro BNP to the baseline level of NT-pro BNP
At enrollment and at 12 months
New York Heart Association (NYHA) class at 12 months compared to baseline
Tidsramme: At enrollment and at baseline
Comparison of the NYHA class at 12 months with the NYHA class at baseline
At enrollment and at baseline
Kansas City Cardiomyopathy Questionnaire (KCCQ) score at 12 months compared to baseline
Tidsramme: At enrollment and at 12 months
Comparison of the KCCQ score at 12 months with the KCCQ score at baseline
At enrollment and at 12 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Ceric Sàrl

Efterforskere

  • Ledende efterforsker: Thibault Lhermusier, MD, PhD, CHU Rangueil

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. august 2026

Primær færdiggørelse (Anslået)

31. august 2027

Studieafslutning (Anslået)

31. august 2027

Datoer for studieregistrering

Først indsendt

5. maj 2026

Først indsendt, der opfyldte QC-kriterier

5. maj 2026

Først opslået (Faktiske)

11. maj 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

13. maj 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

11. maj 2026

Sidst verificeret

1. maj 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • EDW-07

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

No plan has been established in the protocol

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Venstre ventrikulær dysfunktion

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Ghana

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner